Key barriers against racial and ethnic minority participation in U.S. clinical trials

Ashley S. Bae


Despite the United States’ (U.S.) longstanding history of promoting a melting pot nation of people from diverse racial and ethnic backgrounds all capable of achieving the American Dream, it is argued that the U.S. is failing to deliver high quality healthcare to all of its constituents equally. The widely seen health disparities of ethnic minority groups endure has extended into the parallel field of clinical research and clinical trials. There is a staggering gap between the percentage of White clinical trial participants compared to clinical trial participants of racially and ethnically diverse minority groups in U.S. clinical trials. Underrepresentation of minority groups in clinical trials dismisses opportunities to identify potential serious sub-group safety or efficacy signals, open doors to access life-saving treatments, and ultimately improve the standard of evidence-based medicine in the United States. Current literature on this issue frequently reiterates the following five key barriers underrepresented minority groups face against clinical trial participation: mistrust, lack of awareness and access, cultural and language barriers, investigator and provider bias, and financial burdens. A deeper dive into understanding each barrier will be critical in implementing changes with actions and in perspectives in order to address the issue of poor racial and ethnic representation in clinical trial populations.


Clinical trial participation, Barriers, Diversity, Underrepresented minorities, Race, Ethnicity

Full Text:



United States Census Bureau. 2020 Census Illuminates Racial and Ethnic Composition of the Country, 2021. Available at: https://www.census. gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html. Accessed on 27 February 2022.

United States Census Bureau. Demographic Turning Points for the United States: Population Projections for 2020 to 2060, 2020. Available at: Accessed on 28 February 2022.

Sharma A, Palaniappan L. Improving diversity in medical research. Nat Rev Dis Primers. 2021;7(74):1-2.

Oh S, Galanter J, Thakur N, Pino-Yanes M, Barcelo NE, White MJ, et al. Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled. PLoS Medicine. 2015;12(12):1-9.

Charles RMH, Sosa E, Patel M, Erhunmwunsee L. Health Disparities in Recruitment and Enrollment in Research. Thoracic Surgery Clinics. 2022;32(1):75-82.

George S, Duran N, Norris K. A Systematic Review of Barriers and Facilitators to Minority Research Participation Among African Americans, Latinos, Asian Americans, and Pacific Islanders. American Journal of Public Health. 2014:104(2):e16-31.

Clark LT, Watkins L, Piña IL, Elmer M, Akinboboye O, Gorham M, et al. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Current Problems in Cardiology. 2019;44(5):148-72.

National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research, 2017. Available at: /women-and-minorities/guidelines.html. Accessed on 27 February 2022.

National Institutes of Health. NIH Research, Condition, and Disease Categorization (RCDC) Inclusion Statistics Report, 2019. Available at: Accessed on 27 February 2022.

American Cancer Society. Cancer Disparities in the Black Community, 2022. Available at: Accessed on 27 February 2022.

Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021. Available at: /publications-resources/CKD-national-facts.html%20. Accessed on 27 February 2022.

Food and Drug Administration Gender Studies in Product Development: Historical Overview, 2018. Available at: Accessed on 27 February 2022.

Food and Drug Administration. FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials, 2018. Available at: Accessed on 27 February 2022.

Food and Drug Administration. FDA Report Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products, 2013. Available at: Accessed on 27 February 2022.

Food and Drug Administration. FDA Basics Webinar-April 27, 2015: Drug Trials Snapshots, 2017. Available at: Accessed on 27 February 2022.

Getz KA, Smith ZP, Peña Y. Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017. Therapeutic Innovation & Regulatory Science. 2020;54(6):1541-50.

Food and Drug Administration. FDA Reauthorization Act of 2017 (FDARA), 2018. Available at: Accessed on27 February 2022.

Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry, 2020. Available at: Accessed on 27 February 2022.

Library of Congress. H.R.913 - CLINICAL TREATMENT Act, 2019. Available at: Accessed on 01 March 2022.

Stronks K, Wieringa NF, Hardon A. Confronting diversity in the production of clinical evidence goes beyond merely including under-represented groups in clinical trials. Trials. 2013;14(1).

Center for Disease Control and Prevention. The U.S. Public Health Service Syphilis Study at Tuskegee, 2021. Available at: gee/index.html. Accessed on 02 March 2022.

Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. Journal of Heath Care for the Poor and Underserved. 2010;21(3):879-97.

Fisher JA, Kalbaugh CA. Challenging assumptions about minority participation in US clinical research. American journal of public health. 2011;101(12):2217-22.

Bruner DW, Jones M, Buchanan D. Reducing cancer disparities for minorities: A multidisciplinary research agenda to improve patient access to health systems, clinical trials, and effective cancer therapy. Journal of Clinical Oncology. 2006;24(14):2209-15.

Institute of Medicine. Challenges in Clinical Research. In: Institute of Medicine’s Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. 1st ed. Washington DC: National Academies Press. 2010;14-28.

McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. New England Journal of Medicine. 2003;348(26):2635-45.

Gabler S, Barrios A, Kakishita S, Cufino D, Frost CJ. Increasing diversity in research through dedicated language access services. Contemporary Clinical Trials. 2021;106(106439).

American Academy of Arts and Sciences. Main Languages Spoken at Home by U.S. Residents Aged Five Years and Older, 2008–2010, 2016. Available at: Accessed on 07 March 2022.

Williams CP, Senft Everson N, Shelburne N, Norton WE. Demographic and Health Behavior Factors Associated With Clinical Trial Invitation and Participation in the United States. JAMA Network Open. 2021;4(9):e2127792.

Howerton MW, Gibbons MC, Baffi CR, Gary TL, Lai GY, Bolen S, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007;109(3):465-76.

Kusnoor SV, Villalta-Gil V, Michaels M, Joosten Y, Israel TL, Epelbaum MI, et al. Design and implementation of a massive open online course on enhancing the recruitment of minorities in clinical trials - Faster Together. BMC Medical Research Methodology. 2021;21(1).

Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncology. 2016;2(1):137-9.

Nipp RD, Powell E, Chabner B, Moy B. Recognizing the Financial Burden of Cancer Patients in Clinical Trials. The Oncologist. 2015;20(6):572-5.

Symes YR, Modell JG. What Drug Development Sponsors, Contract Research Organizations, and Investigators Can Do to Increase Diversity in Clinical Trials. Journal of Clinical Pharmacology. 2020;60(3):281-3.